Skip to content
Search

Latest Stories

UK to speed up Covid-19 testing as criticism grows

Britain's government said on Wednesday (1) it would ramp up the number of coronavirus tests amid widespread criticism that it was doing far too few, as ministers suggested that shortages of chemicals were partly to blame.

Officials say testing for Covid-19 is key to fighting it, not least to check if medics on the frontline of the epidemic could return to work.


But while Germany has been testing about 500,000 people a week, Britain's current capacity is just 12,750 a day, a figure the government said it was aiming to double by mid-April.

"I hope on testing ... you will see significant increases this week. We expect to be at 15,000 tests over the course of this week and then moving further forward in the future," housing minister Robert Jenrick told broadcaster ITV.

"We do need to go further and we need to do that faster."

The number of coronavirus deaths in Britain rose to 1,789 people, figures on Tuesday (31) showed, a 27 per cent  increase in a day with one of the victims a 13-year-old boy with no apparent underlying health conditions.

So far, tests have been focused on those suspected to have the virus who have been admitted to hospital but the government says it is trying to extend this to key staff in the National Health Service (NHS).

Jenrick said more than 900 health workers were tested over the weekend and a further 8,240 individuals on Monday, as he faced a barrage of questions in media interviews about the low number of tests.

"Fix Testing Fiasco Now," the Daily Mail newspaper said on its front page.

At a news conference on Tuesday, Cabinet Office minister Michael Gove said shortages of necessary chemicals had been a factor.

"A critical constraint on the ability to rapidly increase testing capacity is the availability of the chemical reagents which are necessary in the testing," he said, saying the government was working with companies worldwide to obtain what was required.

The Chemical Industries Association said that, while there was escalating demand, "there are reagents being manufactured and delivered to the NHS".

"Every business here in the UK and globally is looking at what they can do to help meet the demand as a matter of urgency," it said in a statement.

An opposition Labour lawmaker said the problem was that ministers appeared not to have ordered enough of the chemicals from companies that had offered to make what the government needed.

"These are often the same chemical companies which are producing chemicals for the tests in Germany," Bill Esterson said.

"Companies in the UK can make them. They haven't been asked. The shortage is because they haven't been ordered."

Asked about the apparent discrepancy between the government and industry over the shortages, Jenrick said several chemicals were required, "and not all of them, as I understand it, have always been available in the UK in the quantities that we need."

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less